Novartis Diovan Gets Heart Failure Claim But Is Second Line To ACE Inhibitors
Executive Summary
Novartis' Diovan approval for the treatment of heart failure makes the drug the first angiotensin II receptor blocker to carry the indication, but limits it to patients who cannot take ACE inhibitors
You may also be interested in...
FDA Broadens Diovan Heart Failure Indication Based On Atacand Clinical Data
FDA has cleared Novartis' angiotensin II receptor blocker Diovan (valsartan) for first-line use in the treatment of heart failure using data generated by AstraZeneca for its ARB Atacand (candesartan)
FDA Broadens Diovan Heart Failure Indication Based On Atacand Clinical Data
FDA has cleared Novartis' angiotensin II receptor blocker Diovan (valsartan) for first-line use in the treatment of heart failure using data generated by AstraZeneca for its ARB Atacand (candesartan)
Atacand Approval Provides Alternative To ACE Inhibitors For Heart Failure
AstraZeneca's angiotensin receptor blocker Atacand can be used as an alternative to angiotensin-converting enzyme inhibitors in reducing risk of cardiovascular mortality and hospitalization in heart failure patients